<DOC>
	<DOCNO>NCT00541112</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , capecitabine , oxaliplatin , fluorouracil , leucovorin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving radiation therapy together combination chemotherapy cetuximab surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy cetuximab surgery may kill tumor cell remain surgery . PURPOSE : This phase II clinical trial study well give radiation therapy together chemotherapy cetuximab follow surgery , chemotherapy , cetuximab work treat patient locally advance metastatic rectal cancer remove surgery .</brief_summary>
	<brief_title>Radiation Therapy , Chemotherapy , Cetuximab Followed Surgery , Chemotherapy , Cetuximab Treating Patients With Locally Advanced Metastatic Rectal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete remission rate 6 month neoadjuvant radiotherapy , capecitabine , oxaliplatin ( XELOX ) , cetuximab follow surgery , adjuvant FOLFOX 4 , cetuximab patient synchronous locally advanced metastatic cancer rectum resectable metastasis ( T3-4 Nx T2 N+ M1 ) . Secondary - Determine progression-free survival . - Determine overall survival . - Assess toxicity . - Evaluate objective response patient measurable metastasis . - Determine rate local recurrence . - Evaluate downstaging downsize patient operable disease . - Evaluate surgical complication patient operable disease . - Evaluate biological marker predictive response cetuximab . OUTLINE : This multicenter study . - Neoadjuvant therapy : Patients undergo radiotherapy 5 week receive concurrent oral capecitabine twice daily day 1-5 week oxaliplatin IV 2 hour day 1 week ( XELOX ) . Patients also receive cetuximab IV day 1 first week day 1-7 week 2-5 . - Surgery : At 6 week complete chemoradiotherapy , patient resectable disease undergo surgery comprise total mesorectal excision . Patients progressive disease , nonresectable tumor , require R2 surgery remove study . - Adjuvant therapy : Patients undergo surgery , without removal metastasis , receive FOLFOX 4 , comprise oxaliplatin IV 2 hour , fluorouracil IV 46 hour , leucovorin calcium IV day 1 , cetuximab IV . Treatment repeat every 2 week 6 course ( approximately 3 month ) . Patients undergone prior surgical resection metastasis may surgery remove metastasis complete second regimen chemotherapy . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum Locally advance ( T34 Nx ) metastatic ( T2 N+ M1 ) synchronous disease Metastases must resectable Primary tumor examine endorectal echography MRI Measurable disease thoracoabdominopelvic scanner Disease consider susceptible treatment radiotherapy chemotherapy No diffuse metastasis consider nonresectable No acute occlusion cause colostomy PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 WBC ≥ 4,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Creatinine ≤ 130 µmol/L Transaminases ≤ 5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Contraindication therapy capecitabine , oxaliplatin , cetuximab , and/or radiotherapy Impossible perform translational analysis Uncontrolled severe illness Severe renal hepatic insufficiency Cardiac insufficiency symptomatic coronary disease Sensitive peripheral neuropathy Uncontrolled diabetes Other malignancy within past 10 year except previously treat basal cell skin cancer carcinoma situ cervix Impossible participate study due geographic , social , psychiatric reason Patients supervision incarcerate PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior anticancer chemotherapy radiotherapy cancer No therapy coumarin anticoagulant , phenytoin , sorivudine , brivudine , antacid , allopurinol No concurrent participation another therapeutic study receive another experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>